Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the average volume of 53 put options.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Verition Fund Management LLC acquired a new stake in Maravai LifeSciences in the first quarter valued at $925,000. Walleye Capital LLC acquired a new stake in Maravai LifeSciences in the 1st quarter valued at about $858,000. Cantor Fitzgerald L. P. acquired a new position in Maravai LifeSciences during the first quarter valued at approximately $3,210,000. The Manufacturers Life Insurance Company bought a new position in Maravai LifeSciences in the first quarter worth $1,975,000. Finally, Weiss Multi Strategy Advisers LLC bought a new position in shares of Maravai LifeSciences during the first quarter valued at $379,000. Institutional investors own 50.18% of the company’s stock.
A number of equities research analysts have issued reports on the stock. Morgan Stanley reduced their target price on shares of Maravai LifeSciences from $59.00 to $54.00 and set an “overweight” rating on the stock in a report on Friday, February 25th. Robert W. Baird reduced their target price on shares of Maravai LifeSciences from $48.00 to $40.00 in a report on Friday, May 6th.
Shares of NASDAQ MRVI traded down $1.08 during midday trading on Thursday, hitting $25.73. The company had a trading volume of 14,573 shares, compared to its average volume of 1,934,326. The company has a quick ratio of 6.55, a current ratio of 7.14 and a debt-to-equity ratio of 0.80. Maravai LifeSciences has a twelve month low of $23.16 and a twelve month high of $63.55. The business has a 50-day simple moving average of $32.42 and a two-hundred day simple moving average of $34.62. The firm has a market capitalization of $6.57 billion, a price-to-earnings ratio of 16.86 and a beta of 0.76.
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It’s lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last announced its earnings results on Thursday, May 5th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.11. The company had revenue of $244.30 million during the quarter, compared to analysts’ expectations of $232.29 million. Maravai LifeSciences had a net margin of 25.25% and a return on equity of 96.51%. The firm’s quarterly revenue was up 64.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 earnings per share. On average, equities analysts forecast that Maravai LifeSciences will post 1.85 EPS for the current year.
Maravai LifeSciences Company Profile (Get Rating)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Maravai LifeSciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Maravai LifeSciences wasn’t on the list.
While Maravai LifeSciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.